• Alaunos Therapeutics announced new preclinical analysis from its previously reported 48-day DIO mouse study of ALN1003, so results have already been presented.
• The updated analysis reinforced a liver-related benefit signal that appeared to extend beyond changes in body fat, supporting continued development of the oral metabolic candidate.
• The company framed the findings as supportive of further controlled studies to assess dosing, tolerability, and liver biology relevant to metabolic liver disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alaunos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-286914), on June 29, 2026, and is solely responsible for the information contained therein.